RECORDATI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.1 EUR | +0.61% |
|
-1.29% | +0.55% |
| Apr. 24 | Global markets live: Heineken, AT&T Hasbro, Visa, Boeing... |  |
| Apr. 24 | CVC Said Mulling Options for Majority Stake in Recordati | MT |
| Sales 2024 * | 2.3B 2.46B | Sales 2025 * | 2.44B 2.61B | Capitalization | 10.11B 10.81B |
|---|---|---|---|---|---|
| Net income 2024 * | 477M 510M | Net income 2025 * | 523M 559M | EV / Sales 2024 * | 4.97 x |
| Net Debt 2024 * | 1.31B 1.4B | Net Debt 2025 * | 1.07B 1.15B | EV / Sales 2025 * | 4.59 x |
| P/E ratio 2024 * |
22
x | P/E ratio 2025 * |
19.7
x | Employees | 4,455 |
| Yield 2024 * |
2.86% | Yield 2025 * |
3.15% | Free-Float | 46.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Recordati
More press releases
More news
| 1 day | +0.61% | ||
| 1 week | -1.29% | ||
| Current month | -4.18% | ||
| 1 month | -5.58% | ||
| 3 months | -1.76% | ||
| 6 months | +11.67% | ||
| Current year | +0.55% |
1 week
48.38
53.40
1 month
48.3853.40
Current year
47.2953.40
1 year
40.0553.40
3 years
34.5257.90
5 years
28.2657.90
10 years
11.1257.90
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
Luigi la Corte
DFI | Director of Finance/CFO | 54 | 19-10-31 |
Andrea Recordati
CHM | Chairman | 52 | 98-04-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cathrin Petty
BRD | Director/Board Member | 50 | 18-06-11 |
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
Andrea Recordati
CHM | Chairman | 52 | 98-04-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.52% | 5 M€ | +12.55% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 49.1 | +0.61% | 273,233 |
| 24-04-25 | 48.8 | -2.36% | 351,638 |
| 24-04-24 | 49.98 | -4.98% | 478,220 |
| 24-04-23 | 52.6 | +2.94% | 390,244 |
| 24-04-22 | 51.1 | +2.49% | 474,728 |
Real-time Borsa Italiana, April 26, 2024 at 11:44 am EDT
More quotes
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
49.1
EUR
Average target price
52.14
EUR
Spread / Average Target
+6.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.55% | 10.76B | |
| +25.83% | 653B | |
| +27.00% | 556B | |
| -6.76% | 354B | |
| +20.34% | 331B | |
| +3.00% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.26% | 144B |
- Stock Market
- Equities
- REC Stock
